Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 24 (1) , 91-104
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline Biologicals SA
- GlaxoSmithKline Biologicals SA
This publication has 45 references indexed in Scilit:
- Immunisation against meningococcus BThe Lancet, 2013
- Immunisation against meningococcus BThe Lancet, 2013
- Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impactVaccine, 2013
- The Disease Burden of Invasive Meningococcal Serogroup B Disease in CanadaThe Pediatric Infectious Disease Journal, 2013
- The changing and dynamic epidemiology of meningococcal diseaseVaccine, 2012
- Long‐Term Effects of Child Death on Parents' Health‐Related Quality of Life: A Dyadic AnalysisFamily Relations, 2010
- Life expectancy in cerebral palsy: an updateDevelopmental Medicine & Child Neurology, 2008
- Social Contacts and Mixing Patterns Relevant to the Spread of Infectious DiseasesPLOS Medicine, 2008
- Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UKPharmacoEconomics, 2008
- Combination Vaccine Against Invasive Meningococcal B and Pneumococcal InfectionsPharmacoEconomics, 2006